241 blood cancer drugs are in the pipeline

04/29/2013 | Drug Store News

The pipeline of blood cancer treatments in clinical testing or being reviewed by the FDA includes 241 drugs, according to the Pharmaceutical Research and Manufacturers of America. Ninety-eight of the drugs are being developed for the treatment of lymphoma, while 97 are being developed for leukemia, 52 for multiple myeloma and 24 for other cancers of the bone marrow, blood and lymph nodes.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC